Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $917.00 Price Target at Barclays

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price lowered by Barclays from $923.00 to $917.00 in a research report released on Thursday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

Other equities analysts have also issued reports about the company. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $801.00 to $796.00 and set a “buy” rating on the stock in a research report on Thursday. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a research report on Monday, March 2nd. Zacks Research lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $800.00 price target on shares of Regeneron Pharmaceuticals in a research report on Thursday, April 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $825.68.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $707.06 on Thursday. The company has a current ratio of 4.15, a quick ratio of 3.39 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $74.75 billion, a PE ratio of 17.23, a price-to-earnings-growth ratio of 1.58 and a beta of 0.40. The business’s 50-day moving average price is $756.81 and its 200-day moving average price is $735.17. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The company’s revenue was up 19.0% on a year-over-year basis. During the same period in the prior year, the company earned $8.22 EPS. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 35.98 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Wednesday, May 20th will be given a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.16%.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total transaction of $1,279,818.54. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director owned 17,803 shares in the company, valued at approximately $13,860,169.59. The trade was a 0.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 3,774 shares of company stock worth $2,942,738 in the last ninety days. 7.02% of the stock is owned by insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of REGN. Brighton Jones LLC lifted its holdings in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth approximately $226,000. Arrowstreet Capital Limited Partnership purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $3,183,000. Gabelli Funds LLC lifted its holdings in Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after buying an additional 55 shares during the period. Finally, Sei Investments Co. lifted its holdings in Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after buying an additional 5,120 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Q1 beat on both profit and sales: non‑GAAP EPS $9.47 vs. consensus ~ $9.10 and revenue ~$3.6B (+19% y/y), driven by Dupixent strength. This is the primary catalyst supporting the stock today. Regeneron beats quarterly results estimates on strong Dupixent demand
• Positive Sentiment: Board approved up to $3.0B share repurchase program — a direct return‑of‑capital move that typically supports the share price. Analysts and headlines flagged the buyback alongside the earnings beat. Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
• Positive Sentiment: Quarterly cash dividend declared ($0.94 per share, record May 20, payable June 4) — adds a modest yield and supports income‑oriented holders.
• Neutral Sentiment: Pipeline updates: multiple C5 program milestones (PNH enrollment completion) and positive phase III data for cemdisiran in gMG with regulatory submissions underway — bullish for long‑term valuation but timing and commercial execution remain uncertain. Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation
• Neutral Sentiment: GAAP net income fell ~10% to $727M despite revenue growth (non‑GAAP metrics look stronger) — suggests some one‑time items/adjustments that investors should parse in the quarter’s detail. Regeneron Q1 2026 net income falls 10% to $727m
• Negative Sentiment: EYLEA concerns: U.S. sales of high‑dose EYLEA came in below expectations and total EYLEA sales declined y/y, highlighting intensifying competition in the retina market — this is why shares slipped immediately after the print for some investors. Regeneron Slumps On An Unexpected Setback For Its Bread-And-Butter Drug
• Negative Sentiment: Several firms trimmed price targets and forecasts post‑earnings (RBC, Wells Fargo, Truist, Barclays among others) — analysts cite mix shifts and competitive risk, which could cap near‑term upside despite the buyback. Analysts Cut Forecasts Following Q1 Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.